[
  {
    "ts": null,
    "headline": "This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131%",
    "summary": "Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.",
    "url": "https://finnhub.io/api/news?id=9255dcd5a9df1e8ffa7e233d79b507f571084aec9134431fa288727bf473480e",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766765245,
      "headline": "This Cancer-Fighting Biotech Surges Into Buy Zone As Earnings Soar 131%",
      "id": 137908172,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Investors gave been rotating away from technology. This biotech stock has rallied into a buy zone amid sharp earnings growth.",
      "url": "https://finnhub.io/api/news?id=9255dcd5a9df1e8ffa7e233d79b507f571084aec9134431fa288727bf473480e"
    }
  },
  {
    "ts": null,
    "headline": "Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?",
    "summary": "CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.",
    "url": "https://finnhub.io/api/news?id=7536ba9ca57b277c7e0ae2c4b1d5781f5a1c21642e4458299fb0f5f31902ae14",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766758320,
      "headline": "Can CorMedix's Melinta Acquisition Aid Growth Beyond DefenCath?",
      "id": 137908338,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "CRMD's $300M Melinta acquisition adds seven products and helps raise 2025 revenue guidance, but questions remain over easing DefenCath reliance.",
      "url": "https://finnhub.io/api/news?id=7536ba9ca57b277c7e0ae2c4b1d5781f5a1c21642e4458299fb0f5f31902ae14"
    }
  },
  {
    "ts": null,
    "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
    "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
    "url": "https://finnhub.io/api/news?id=311746bc5986f457a8884d6e1ecdb371c5d806ee97d57716639bd890a3fb21b4",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766757604,
      "headline": "Pfizer Inc. (PFE) Is a Trending Stock: Facts to Know Before Betting on It",
      "id": 137908339,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "Pfizer (PFE) has received quite a bit of attention from Zacks.com users lately. Therefore, it is wise to be aware of the facts that can impact the stock's prospects.",
      "url": "https://finnhub.io/api/news?id=311746bc5986f457a8884d6e1ecdb371c5d806ee97d57716639bd890a3fb21b4"
    }
  },
  {
    "ts": null,
    "headline": "Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?",
    "summary": "JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.",
    "url": "https://finnhub.io/api/news?id=dcf5123ba9580eba7d39982e39990d06e3257f2a4a13d9121dbb0b3c41f7ddea",
    "source": "Yahoo",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766755260,
      "headline": "Can J&J's Pipeline Progress in 2025 Aid Long-Term Growth?",
      "id": 137908173,
      "image": "https://s.yimg.com/rz/stage/p/yahoo_finance_en-US_h_p_finance_2.png",
      "related": "PFE",
      "source": "Yahoo",
      "summary": "JNJ's rapidly advancing pipeline, new drug approvals and expanding cancer and neuroscience portfolio could fuel growth through the next decade.",
      "url": "https://finnhub.io/api/news?id=dcf5123ba9580eba7d39982e39990d06e3257f2a4a13d9121dbb0b3c41f7ddea"
    }
  },
  {
    "ts": null,
    "headline": "Can Amgen Sustain Its Rally In 2026",
    "summary": "Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.",
    "url": "https://finnhub.io/api/news?id=3206d8bcffd059c1f673da6ff56b46640d3bb167e099f635b7cf60fcdeed5ba9",
    "source": "SeekingAlpha",
    "provider": "finnhub",
    "raw": {
      "category": "company",
      "datetime": 1766754208,
      "headline": "Can Amgen Sustain Its Rally In 2026",
      "id": 137908908,
      "image": "https://static.seekingalpha.com/cdn/s3/uploads/getty_images/1023666022/image_1023666022.jpg?io=getty-c-w1536",
      "related": "PFE",
      "source": "SeekingAlpha",
      "summary": "Amgen Inc. raises 2025 revenue guidance on strong Repatha and Imdelltra sales and dividend hike. Click for this AMGN update.",
      "url": "https://finnhub.io/api/news?id=3206d8bcffd059c1f673da6ff56b46640d3bb167e099f635b7cf60fcdeed5ba9"
    }
  }
]